Radiation and chemotherapeutic drugs for cancer produce prolonged and often irreversible gonadal damage. To determine whether total body irradiation (TBI)-induced gonadal damage can be prevented by suppression of pituitary gonadotrophin levels, we studied a patient with transfusion dependent homozygous betathalassaemia and acute lymphoblastic leukaemia (ALL) who underwent one-antigen mismatched related bone marrow transplantation (BMT). Our data showed that despite having hypogonadotrophic hypogonadism (HH) prior to BMT, the patient developed primary testicular failure following the procedure, indicating that hypogonadotrophism failed to offer protection against TBIinduced testicular damage in this patient. Although this is an interesting case report, no firm conclusions can be drawn from a single patient. Bone Marrow Transplantation (2001) 28, 989-991. Keywords: hypogonadotrophic hypogonadism; acute lymphoblastic leukaemia; thalassaemia; bone marrow transplantation As the number of recipients of high-dose chemoradiotherapy for haematological and other malignancies making a full recovery continues to rise, there is growing concern about the impact of the sterilising effects of such treatment, especially in young adult survivors.
As the number of recipients of high-dose chemoradiotherapy for haematological and other malignancies making a full recovery continues to rise, there is growing concern about the impact of the sterilising effects of such treatment, especially in young adult survivors. 1 The concept of protection of spermatogenic function from cytotoxic damage stems from the original study of Glode et al, 2 who showed gonadal protection in a prepubertal mouse model by administering gonadotrophin-releasing hormone (GnRH)-agonist during and after cyclophosphamide treatment which is presumed to result in a resting testicular state, thereby rendering spermatogonia quiescent and resistant to chemotherapy. There is no human study to determine the effect of GnRHagonist towards preventing gonadal damage following radiotherapy, and only conflicting results 3, 4 are available from animal studies. Recently we have shown in a patient with CLL that GnRH administration can protect against fludarabine-induced testicular damage. 5 As there are interspecies differences in the patterns of recovery of spermatogenesis after cytotoxic drugs, 4 animal data cannot be extrapolated to humans. Also the exact dose, timing and frequency of administration of GnRH for induction of medical hypogonadotrophism in the BMT setting is not fully established. Thus, it is impossible to have an ideal model to study the protective effect of GnRH on spermatogenesis in recipients of chemotherapy or radiotherapy.
Case report
To determine whether high-dose chemo-radiotherapy induced testicular failure can be prevented by hypogonadotrophism, we studied a 34-year-old patient with beta-thalassaemia major and ALL, who underwent a one-antigen mismatched related donor bone marrow transplant. The haematological data have been published before. 6 In summary, he received induction chemotherapy according the MRC ALLX protocol (vincristine, prednisolone, asparaginase, etoposide, cytarabine, thioguanine, daunorubicine), and subsequently a one-antigen mismatched related donor bone marrow transplant. Conditioning consisted of cyclophosphamide 60 mg/kg/day for 2 days and total body irradiation (TBI) at a dose of 1440 cGy in eight fractions.
He was studied longitudinally for 36 months (before, during and 18 months post transplant). He had had spontaneous puberty and had fathered two children, the youngest being born 4 years prior to the transplant. Subsequently he had adult onset HH secondary to transfusional haemosiderosis, thus allowing him to operate as a 'naturally' occurring model for our hypothesis. At presentation, he had undetectable gonadotrophins (FSH and LH), very low testosterone (T) levels and reduced testicular volume (8 ml). He underwent dynamic assessment of the pituitary-testicular axis by a standard protocol, published previously. 7 Gonadotrophin sufficiency was tested by using a 100 g dose of i.v. bolus GnRH and blood was sampled at 20 min intervals for 3 h and assayed for FSH and LH levels. Testicular function was assessed by the human chorionic gonado-trophin (HCG) stimulation test after injecting (i.m.) 4000 IU of HCG and measuring T levels for 4 consecutive days. The patient had severe hypogonadotrophism as shown by unchanged basal FSH and LH levels (data not given). Although he had low basal T levels, he had a functionally intact testis as substantiated by normal human chorionic gonadotrophin (HCG)-stimulated T levels. Table 1 shows the clinical and the endocrine data of the patient before and after transplantation. Following BMT, he had primary testicular failure as evident from a markedly reduced testicular volume (from 8 to 3 ml), low basal as well as HCG stimulated T levels (Table 1 ) and persistent azoospermia. In fact, the patient had evidence of azoospermia on four semen samples, done 6 months apart. Interestingly, one of the conventional markers of primary gonadal failure (significantly high gonadotrophins) was absent in this patient due to concomitant hypogonadotrophism. Thus his post-transplant gonadotrophins remained undetectable. Clearly, this patient who had HH prior to high-dose therapy (very low basal and GnRH-stimulated gonadotrophin levels), developed primary testicular failure after BMT.
Discussion
This case report, the first known in the literature, supports our tested hypothesis that hypogonadotrophism fails to protect from testicular damage induced by TBI-based regimens in an adult recipient of BMT. Although no comparable data exist for the human testis, in agreement with our observation, Gosden et al 8 has shown in the mouse ovary that congenital or experimentally induced hypogonadotrophism fails to protect against ovarian injury inflicted by total body irradiation.
Hypogonadotrophic hypogonadism (HH) is the most common endocrinopathy, affecting patients with thalassaemia major worldwide. 9 Although HH is potentially reversible in the early stages, 7 it is usually irreversible with evidence of structural loss of the anterior pituitary in thalassaemic adults. However, induction of spermatogenesis may still be feasible by using exogenous gonadotrophins, as thalassaemic patients Table 1 Endocrine data before and after BMT often have potentially intact gonadal function even at a late stage of the disease. 10 However, in contrast to patients with idiopathic HH who usually respond within 3-6 months, in thalassaemia patients response normally takes longer (2 years or more), due to diminished gonadal reserve caused by iron overload (Chatterjee, personal observations).
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Various studies on growth and sexual performance in thalassaemic children treated by allogeneic BMT have suggested that many pre-and peripubertal children under the age of 17-18 years, with suspected hypogonadotrophism (from transfusional haemosiderosis) enter puberty, albeit delayed, despite suffering damage to their pituitary gonadal axis. However, these data cannot be extrapolated to adult thalassaemics with HH. Pre-pubertal and peri-pubertal children have immature hypothalamic-pituitary-gonadal axes and suffer less gonadal damage than the adults, as evident from the original work of Glode et al. 2 Additionally, the conditioning regimens used in these studies included chemotherapeutic agents and not TBI.
In summary, this interesting case report of an adult thalassaemic with HH and ALL, is the first to test whether radiotherapy-induced gonadal damage can be prevented by the co-existing endogenous hypogonadotrophism. Since allogeneic transplantation is becoming more popular even in adult patients with thalassaemia, 11 our observation has implications for iron overloaded adult ex-thalassaemics, as well as for leukaemia patients undergoing allogeneic BMT. We have shown in this case report that our patient sustained severe chemo-radiotherapeutic gonadal injury, despite having a functionally intact gonad. Although gonadal recovery is at least theoretically possible in this patient despite severe TBI-induced damage, such a possibility is slim. This information must be made available to all patients undergoing allogeneic transplantation during fertility counselling. In these patients, the best option is to cryopreserve semen samples if possible. Alternatively, the post-transplant option is to use donor gametes, as induction of spermatogenesis is rarely possible after a TBI-containing regimen.
In conclusion, this report shows the inability of endogenous HH to prevent TBI-induced primary testicular failure. However, caution must be exercised in the interpretation of data as they are based on a single case report.
